The associations between cardiovascular disease (CVD) and inhaled long-acting β 2 -agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could act as important determinants of cardiovascular events.
C hronic obstructive pulmonary disease (COPD) is a chronic and irreversible inflammatory lung disease, presently posing a significant burden to health care systems across the world. [1] [2] [3] [4] [5] [6] Long-acting β 2 -agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the mainstay therapies for COPD 7, 8 ; however, these agents were found to increase the risk of cardiovascular disease (CVD), although the findings varied, concluding that there was no increased risk [9] [10] [11] [12] [13] [14] or that there was a 1.1-to 4.5-fold increased cardiovascular risk. [15] [16] [17] [18] These studies, even a large randomized clinical trial (RCT), 9 generally observed few cardiovascular events, excluded patients with severe illness, 9-11 and obtained incomplete medication records 17, 18 as well as dropped more than 50% of eligible patients. 15 All of these limitations could potentially weaken the causality or generalizability of the association. Notably, inclusion of patients with tolerability to the risk of CVD receiving LABA or LAMA therapy is probably a major drawback in previous large RCTs. The 4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial 10 and the 3-year Toward a Revolution in COPD Health (TORCH) trial, 9 which observed a reduced or no increase in CVD risk, included more than 45% and 35% of participants who had received inhaled cholinergics and LABAs, respectively, and the 2 trials excluded patients with a history of recent CVD and life-threatening cardiovascular events. Accordingly, patients who had developed severe CVD with new use of LABAs or LAMAs could have been excluded, and only those LABA or LAMA prevalent users who had probably developed tolerance to the cardiovascular risk were included in the trials. Accordingly, we suspect that new use of and duration since initiating LABAs and LAMAs could act as important determinants of CVD risk, which to date have not been examined in details in previous studies. The present study investigated use of LABAs and LAMAs associated with the risk of CVD in a nationwide population of patients with COPD, focusing on new use and duration of therapy, individual agents, dosage forms, and concomitant COPD regimens.
Methods

Study Design and Data Source
We performed a nested case-control study of a nationwide COPD population 40 years or older with the data retrieved from the Taiwan National Health Insurance Research Database (NHIRD) from January 1, 2007 , to December 31, 2011 , as depicted in eFigure 1 in the Supplement. The NHIRD contains all medical and pharmacy claims records from all medical care settings for more than 99% of the 23 million Taiwanese inhabitants covered under a compulsory and universal national health insurance. The claims are audited quarterly by the National Health Insurance Administration, 19 and multiple disease diagnosis codes in the database have been validated, including several CVD diagnoses. [20] [21] [22] The study was exempt from a full review by the institutional review board of Tri-Service General Hospital, National Defense Medical Center.
Identification of Study Cohort
We identified patients with COPD 40 years or older who had made 2 outpatient visits or an inpatient visit for COPD (International Classification of Diseases, Ninth Revision [ICD-9] codes 491.xx, 492.xx, and 496.xx) in a single year from January 1, 2008 , to June 30, 2011 , accompanied by a record of filling at least 1 COPD medication at each visit. The cohort entry date was set as the date of the first COPD outpatient visit or the discharge date from a COPD hospitalization. We excluded patients who had received any LABA-LAMA therapy or who lacked continuous health insurance coverage for 1 year preceding cohort entry. We followed-up the remaining patients until the earliest of CVD outcome (defined in the outcome measurement), National Health Insurance program withdrawal, death, or the end of the study period (December 31, 2011) . We determined mortality from the NHIRD based on a previously reported approach.
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Case Identification
We identified CVD cases as patients who had made an inpatient or emergency department (ER) visit with a primary diagnosis of coronary heart disease (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM], codes 410-414), cardiac arrhythmia (code 427), heart failure (code 428), or ischemic stroke (codes 433-434). The adopted coding system for acute myocardial infarction, heart failure, and ischemic stroke has been validated with high accuracy. 20, 21, 24 We set the first CVD event as the index date. Each case was matched to 4 randomly selected controls from risk set samples by cohort entry date (±180 days) and disease risk score (DRS) (±0.01) of predicting the occurrence of a cardiovascular outcome during follow-up. Use of the DRS to match cases with controls yields better statistical precision than does exact matching on multiple discrete factors in a nested case-control setting.
25 Estimation of the DRS is detailed in eMethods 1 in the Supplement.
Exposure Measurement
We examined all LABA and LAMA prescription records in the year before the index date for both cases and controls. Specifically, drug use was classified into current (≤30 days), 
Key Points
Measurement of Covariates
Important determinants of CVD were considered, such as prior CVDs, hypertension, diabetes, hyperlipidemia, use of CVD medications, and agents related to cardiotoxicity. We also considered proxy indicators of COPD severity, including the number of COPD-related outpatient visits accompanied by oral corticosteroids or respiratory antibiotic prescription records (referred to as moderate exacerbation) and the number of severe exacerbation events (defined as any inpatient or ER admission for COPD), as well as the presence of incident or prevalent COPD. Other factors related to LABA-LAMA use or CVD were considered (as detailed in eTable 1 in the Supplement). We first measured these factors in the year preceding cohort entry, and included them in a logistic regression model to estimate the DRS of encountering a CVD outcome during follow-up (eMethods 1 in the Supplement). Second, we treated these confounders as time-varying effects by also assessing concomitant medications and the remaining factors during the 6 months and in the year prior to the index date, respectively.
Statistical Analysis
The covariate balance before and after DRS matching was assessed using the standardized difference, and meaningful imbalances between groups were determined when the standardized difference was greater than 0.1. 26 We used conditional logistic regressions to estimate the odds ratio (OR) of CVD with LABA or LAMA use. We expressed the absolute risk of CVD arising from LABA and LAMA treatment as the number needed to harm (NNTH) 27 according to a previously reported formula.
Data sets were constructed and analyzed by using SAS (version 9.3; SAS Institute Inc) and STATA (version 13; StataCorp) statistical software, respectively. We defined tests with 2-sided P < .05 as significant.
Sensitivity and Subgroup Analysis
Multiple additional analyses were performed. First, we adopted a case-crossover study to avoid selection bias and minimize time-invariant confounding (eMethods 3 and eFigure 2 in the Supplement). Second, to mitigate confounding by indication bias, we repeated the analyses by treating patients who began new treatment with theophyllines, another class of bronchodilators used for COPD therapy, in the 30 days before the index date as the reference group. Third, to address protopathic bias, we used a lag-time approach 28 that disregarded any prescription records of LABAs and LAMAs in the 7 days before the index date and restricted new LABA and LAMA users to those who received spirometry testing within 30 days before or on the date of initiating these medications to justify respiratory medication use. We also excluded patients who started any cardiovascular medications in the 30 days before the index date and those with any chest pain (ICD-9 code 786.5) or dyspnea/breathing difficulty diagnoses (code 786.0) as possible presymptoms of CVD. Fourth, events of heart failure were excluded from the CVD outcome. Fifth, we also performed stratified analyses by CVD care type, baseline CVD status, CVD severity (fatal vs nonfatal), COPD severity, asthma comorbidity, use of theophyllines, and use of systemic short-acting β 2 -agonists. Sixth, we adjusted for all covariates that were measured preceding the index date in Table 1 and evaluated the impact of unmeasured confounding using a rule-out approach, 29 as detailed in eFigure 3 in the Supplement.
Results
The study cohort consisted of 284 220 LABA-LAMA-naive patients with COPD with a mean age of 71.4 years, 68.9% of whom were male. During a mean follow-up of 2.0 years, we identified 37 719 patients with severe CVD requiring hospitalization or emergency care, at a rate of 6.6 per 100 personyears, and included 146 139 matched controls (eFigure 4 in the Supplement). All characteristics were balanced prior to cohort entry between cases and controls ( Table 1) . During follow-up, most of the covariates remained balanced between the 2 groups, and only a few factors differed significantly higher between cases and controls, for which statistical adjustment was performed.
As indicated in Table 2 , overall use of inhaled long-acting bronchodilators was not associated with an increased risk of CVD across different recency of therapy, although a 10% decrease in cardiovascular risk was observed with past LABA use. Among current users, new initiation of LABA and LAMA treatment was associated with a 1.50-fold (95% CI, 1.35-1.67; P < .001) and a 1.52-fold (95% CI, 1.28-1.80; P < .001) increased cardiovascular risk, respectively, while prevalent LABA or LAMA use yielded a 9% to 12% reduction in risk. In addition, new LABA use vs new LAMA use yielded no difference in the risk of CVDs (P = .93) (eTable 2 in the Supplement).
Various clinical usages of LABAs and LAMAs within 30 days of therapy initiation were scrutinized ( Table 3 ). The adjusted ORs ranged minimally from 1.42 to 1.51 across the various LABA medication regimens. Salmeterol and formoterol were found to present similar CVD risks. Different LAMA regimens, including use of tiotropium only, carried similar risks, ranging from 1.39-fold to 1.58-fold increases. Analyses of individual CVD outcomes revealed increased risks of coronary artery disease and heart failure with LABA and LAMA treatment, and an increased risk for cardiac arrhythmias with LAMA therapy (eTable 3 in the Supplement). Figure 1 presents the results of duration-response analysis, which indicated that the cardiovascular risks peaked at around the 30th day after new initiation of LABA or LAMA therapy; waned from 31 to 60 days of therapies, and reduced to a level even lower than the baseline risk from 71 to 240 days.
Our main findings remained robust in most of the sensitivity analyses (Figure 2 , eTables 4 and 5, eFigures 2 and 3 in the Supplement). The increased risk of CVD with new LABA and new LAMA use persisted in a case-crossover analysis (eTables 4-5, eFigure 2 in the Supplement) and in comparison with new use of theophyllines. The results of the analyses performed to address protopathic bias corresponded closely to the main findings. The LABA-or LAMA-associated risk of CVDs remained significant regardless of patients' CVD history and COPD exacerbations. In addition, an unmeasured confounder could fully account for our findings only if the confounder increased the CVD risk by 4-fold a All comorbidities and comedications were measured in the year preceding entry date.
b All comorbidities were measured in the year, and comedications in the 6 months before index date.
c Covariates with SDiff> 0.1 represent meaningful differences between groups.
d Prior CVDs were measured in 3 severity levels.
e Severe COPD exacerbation was defined as patients requiring hospital or ER visits for COPD.
f Moderate COPD exacerbation included patients who were prescribed with either an antibiotics or oral corticosteroid in an outpatient COPD visit.
and was more prevalent in new LABA and LAMA users by 3.5 and 3.6 times, respectively, than in nonusers (eFigure 3 in the Supplement). One severe CVD event requiring hospitalization or ER care occurred for every 406 (95% CI, 303-580) new LABA users and 391 (95% CI, 254-725) new LAMA users during the first 30 days of therapy (eTable 6 in the Supplement).
Discussion
This large observational study of more than 280 000 patients with COPD reported an approximate 1.5-fold increased risk of a severe CVD event within 30 days of initiation of LABA or LAMA therapy, but the risk was absent, or even reduced, with [15] [16] [17] [18] 30, 31 examined drug use within a time period as short as 30 days after the initiation of therapy. The ability to observe an acute cardiovascular effect with inhaled long-acting bronchodilators in our study primarily resulted from the adoption of a new-user design and examination of a nationwide population of patients with COPD.
Our observed duration-response associations may explain why previous relevant RCTs did not find an increased risk of CVD with LABA or LAMA use. We report herein that the greatest risk of CVD emerged at around the 30th day following initiation of LABA and LAMA therapy. Nevertheless, a substantial proportion of participants with prior LABA or LAMA usage was included in previous RCTs. [9] [10] [11] [12] 32 For instance, more than one-third of the enrolled patients received LABAs at baseline in the TORCH trial 9 ; therefore, cardiovascular events arising following first use of LABAs or LAMAs, if any, could not be observed. In addition, patients with severe CVD or life-threatening cardiovascular events at baseline were excluded in prior trials. 9-12 Both factors could have led to the inclusion of patients with tolerability to cardiovascular events in the RCTs. The phenomenon of depletion of susceptibles effect may contribute to the observed duration-response associations. Depletion of susceptibles effect has been described as an increased rate of an event from the initial exposure to a medication, followed by a decreased incidence rate with a longer drug exposure, 33, 34 such as the temporal sequence of hormone replacement therapy and its relationship with venous thromboembolism. 34 We suspect that there may exist a subgroup of patients with COPD who are particularly at risk of CVD with initial exposure to LABAs or LAMAs owing to predisposing factors that could amplify sympathetic overactivation or systemic inflammation with inhaled long-acting bronchodilators. Future studies should identify and characterize the most vulnerable subgroups of patients with COPD. We also suspect that after depletion of susceptible patients who experienced CVD events early on, the remaining patients with COPD who continued to use LABAs or LAMAs may exhibit improved systemic inflammation, 35 or may have a more stable lung function status, 36 which could lessen the CVD burden in these patients. Our findings contribute significantly to investigation of the cardiovascular safety of inhaled long-acting bronchodilators, in which the risk window of adverse cardiovascular events from inhalation therapies is specified. Based on our findings, we suggest that the use of inhaled long-acting bronchodilators in COPD need to be carefully assessed, and a thorough cardiovascular physical examination, especially heart rate measurement and electrocardiograms, need to be performed when prescribing LABAs and LAMAs to patients. Health care professionals should be vigilant for any cardiovascular symptoms during the first 30 days of inhalation therapy. Given that CVD is highly prevalent among patients with COPD, clinicians should also pay attention to the management of CVD risk factors throughout the duration of LABA or LAMA therapy. We also suggest that physicians assess patients' cardiovascular risk before initiation of LABAs or LAMAs, and, if needed, a preventive therapy for CVD should be considered during the initial treatment of inhaled long-acting bronchodilators.
Two potential mechanisms have been proposed to underpin the cardiovascular risk arising from LABA and LAMA use. Acting as autonomous nervous system agents, LABAs and LAMAs are believed to cause sympathetic overactivation by activating sympathetic β 2 -adrenergic receptors (β2R) and suppressing parasympathetic muscarinic-3 receptors (M3R), respectively. 6, 37, 38 However, LABA and LAMA use in COPD has been observed to increase the inflammatory cytokine levels, such as an increased level of interleukin-8, 39,40 which could lead to an increased risk of CVD.
Strengths and Limitations
Several important strengths of our study merit discussion. We investigated the whole spectrum of timing and duration effects of LABA and LAMA usage on the development of severe CVD events in a population with COPD, which is a clinically important aspect that, to our knowledge, no study has addressed previously. In addition, this study was the first to examine the effect of LABA-LAMA regimens with various concomitant COPD medications, which provided pivotal information given that COPD care usually involves multiple therapies. Furthermore, a new-user design served to minimize tolerance effects in prevalent drug users. Moreover, our findings can be generalized to the entire COPD population with multiple coexisting comorbidities. Several study limitations of the current report need to be addressed. First, worsening of COPD could have prompted the use of LABAs or LAMAs and caused the observed CVD. To control for this confounding effect, we adjusted for multiple proxies of COPD severity and compared new LABA users and new LAMA users, respectively, with new theophylline users, which yielded consistent results. Second, selection bias may have been present, although this bias was expected to be minimal, because we balanced all covariates at cohort entry between cases and controls, treated them as time-varying effects, and obtained consistent findings with an adopted case-only design. Third, protopathic bias could have existed. Nevertheless, we reached the same conclusions when adopting multiple approaches to address this bias, such as the use of a lag-time approach. Fourth, patients' CVD status at baseline may have confounded our findings. However, we believe this confounding effect not to be substantial because all baseline CVD statuses and CVD medications were balanced between the 2 groups, and the LABA-or LAMA-associated CVD risk remained significant among patients without a CVD history. Fifth, several important determinants of CVD, for example, smoking and alcohol consumption, were unavailable, which could have confounded our findings. However, their effects were unlikely to fully explain our findings, as assessed by rule-out analysis, especially for highly prevalent confounders such as smoking. Sixth, newer LABAs or LAMAs were unable to be assessed, such as aclidinium.
Conclusions
New use of LABAs or LAMAs was associated with a 1.5-fold increased cardiovascular risk in patients with COPD within 30 days of therapy initiation. We caution physicians to closely monitor new users of LABAs or LAMAs for cardiovascular symptoms. Author Contributions: Dr Wang had full access to all of the study data and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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eMethods 1. Development of a disease risk score-matched nested case-control study
A disease risk score (DRS) of encountering the cardiovascular outcome of interest for each patients of the study cohort was estimated. Specifically, we predicted the probability of developing the cardiovascular outcome during the follow-up of the entire study cohort by fitting a multiple conditional logistic regression with all factors considered in the Table 1 , which were measured in the year preceding cohort entry, as well as the exposure status to inhaled long-acting bronchodilators, including inhaled long-acting 2 agonists (LABAs) and long-acting antimuscarinic antagonists (LAMAs) that were measured during the entire follow-up period. The DRS of the cardiovascular outcomes was then computed as the fitted values from the abovementioned logistic regression model for each cohort member when setting the exposure status to inhaled long-acting bronchodilators as no use.
After obtaining the DRS for each cohort member, we matched each case of cardiovascular disease patient with up to 4 controls by cohort entry date (± 180 days) and the DRS (± 0.01) with a greedy matching approach. We detailed the DRS matching scheme as follows. For each case, we selected up to 4 controls that had the closet DRS values as the corresponding case's value, and required the controls' DRS eMethods 2. Modeling a nonlinear duration-response association using a restricted cubic splines function model.
In order to assess the duration of new LABA and LAMA therapies, we restricted LABA or LAMA users to those with at least one prescription record of inhaled long-acting bronchodilators within the 30 days preceding the index/event date, among whom any users of LABAs or LAMAs in the year preceding the index date were excluded. We then calculated continuous use of LABAs and LAMAs using a grace period of 30 days between successive prescriptions.
We further analyzed duration of new LABA and LAMA therapy as a continuous exposure variable, respectively, using restricted cubic splines function models.
Specifically, we fitted the duration-response curves using a restricted cubic spines function with five knots, located at 15, 30, 45, 90, and 180 days in a multiple conditional logistic regression model, which adjusted the covariates with standardized difference > 0.1 listed in Table 1 . eMethods 3. A case-crossover study for assessing the association between the CVD risk and use of LABAs and LAMAs A case-crossover study is a mean to control measured and unmeasured confounders that stay stable over time, in which exposures are compared at individual case levels between two or more time periods preceding the outcomes. From the final 37,719 CVD cases identified in our nested case-control study of COPD patients, we excluded people who did not have at least 120 days of follow-up before their index date, and the remaining CVD patients were included in the case-crossover study (n=27,036).
For each of the 27,036 CVD patients, we defined day 1-30 before the index date as the case period and day 91-120 as the control period (as shown in eFigure 2). The CVD patients were considered exposed if the date that they filled LABA or LAMA prescriptions occurred within the case or the control time period. The odds ratio (OR) of CVD events that required a hospital or an ER visit from exposure to LABA or LAMA was determined using conditional logistic regression models that adjusted for imbalanced covariates between the two time periods (as indicated in eTable 5). 
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